BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  BioCapital

  2021 COVID-19 News: Moderna Pays out $1 Million for Security and More

  Please check out the biopharma industry’s COVID-19 stories that are trending for April 6, 2021.

  April 6, 2021

   · 

  4 min read

   · 

  BioSpace Editorial Staff
• 

  Business

  Valence Discovery Deal Brings Purpose-Built AI/ML to Charles River Labs’ Clients

  Valence Discovery just announced a strategic alliance with Charles River Laboratories to make its artificial intelligence (AI) and machine learning (ML) platform available to Charles River’s clients.

  April 6, 2021

   · 

  4 min read

   · 

  Gail Dutton
• 

  Drug Development

  IDbyDNA’s Metagenomics Suite Future-Proofs Labs for Coming Pathogen Crises

  IDbyDNA’s metagenomic approach to viral strain identification combines very sensitive detection with next-gen sequencing to identify emerging and mutant viruses much sooner than either genomic or surveillance methods alone.

  April 6, 2021

   · 

  4 min read

   · 

  Gail Dutton
• 

  Drug Development

  Current COVID-19 Vaccines are Great. Can They be Better?

  Can they be better? Or perhaps, cheaper and easier to make, especially for developing companies? Researchers at the University of Texas and the PATH Center for Vaccine Innovation and Access think so.

  April 6, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  Volastra’s Strong Year Continues with Microsoft Deal and Extended Seed Financing

  The New York-based company inked a deal with Microsoft to develop unique digital pathology tools for oncology and also announced its seed funding round was extended from $12 million to $44 million.

  April 6, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Gilead CEO Got $19 Million Pay in Blockbuster Year for Company

  Gilead CEO Daniel O’Day navigated the company through the turbulent waters of COVID-19 last year, pushing out the very first approved treatment for treatment of the virus. His reward? A $19 million take home.

  April 6, 2021

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Business

  Brooklyn ImmunoTherapeutics, Overland ADCT BioPharma Name New CEOs

  The biopharmaceutical industry saw two CEO appointments made today, including Howard J. Federoff, M.D., Ph.D., to Brooklyn ImmunoTherapeutics and Eric Koo to Overland ADCT BioPharma.

  April 6, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Job Trends

  AstraZeneca Vaccine Thrombosis Saga Continues with No Clear Answers

  In mid-March, more than a dozen countries suspended the deployment of the AstraZeneca-Oxford University vaccine after incidences of blood clots were reported.

  April 6, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  Mineralys Launches With $40 Million for Hypertension Clinical Asset

  Philadelphia-based Mineralys Therapeutics launched today with a $40 million Series A round to move its clinical asset, MLS-101, into Phase II testing for hypertension.

  April 6, 2021

   · 

  2 min read

   · 

  Mark Zipkin
• 

  Drug Development

  Shareholders Raise Questions on COVID-19 Pricing Ahead of Annual Biopharma Meetings

  Throughout 2020, the U.S. government spent billions of dollars to help finance the development of COVID-19 vaccines and therapeutics. Now, shareholders of the companies that received this financing are eager to see how those public funds will impact the pricing of these treatments.

  April 6, 2021

   · 

  2 min read

   · 

  Alex Keown